Detail akcie Jaguar Health Rg online

Business Summary: Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Jaguar Health Inc revenues increased 1% to $8.3M. Net loss increased 6% to $30.4M. Revenues reflect Human Health segment increase of 1% to $8M, Animal Health segment increase of 19% to $270K. Higher net loss reflects Gain (loss) on extinguishment of debt increase from $1.2M (income) to $1.8M (expense), General and administrative expense - Bal increase of 20% to $9.5M (expense).